370 related articles for article (PubMed ID: 34544752)
21. The mechanisms involved in the resistance of estrogen receptor-positive breast cancer cells to palbociclib are multiple and change over time.
Ono M; Oba T; Shibata T; Ito KI
J Cancer Res Clin Oncol; 2021 Nov; 147(11):3211-3224. PubMed ID: 34244855
[TBL] [Abstract][Full Text] [Related]
22. Cdk4 and Cdk6 cooperate in counteracting the INK4 family of inhibitors during murine leukemogenesis.
Rodríguez-Díez E; Quereda V; Bellutti F; Prchal-Murphy M; Partida D; Eguren M; Kollmann K; Gómez de Cedrón M; Dubus P; Cañamero M; Martínez D; Sexl V; Malumbres M
Blood; 2014 Oct; 124(15):2380-90. PubMed ID: 25157181
[TBL] [Abstract][Full Text] [Related]
23. Selective degradation of CDK6 by a palbociclib based PROTAC.
Rana S; Bendjennat M; Kour S; King HM; Kizhake S; Zahid M; Natarajan A
Bioorg Med Chem Lett; 2019 Jun; 29(11):1375-1379. PubMed ID: 30935795
[TBL] [Abstract][Full Text] [Related]
24. CDK4/6 inhibition synergizes with inhibition of P21-Activated Kinases (PAKs) in lung cancer cell lines.
Wright GM; Gimbrone NT; Sarcar B; Percy TR; Gordián ER; Kinose F; Sumi NJ; Rix U; Cress WD
PLoS One; 2021; 16(6):e0252927. PubMed ID: 34138895
[TBL] [Abstract][Full Text] [Related]
25. p27 allosterically activates cyclin-dependent kinase 4 and antagonizes palbociclib inhibition.
Guiley KZ; Stevenson JW; Lou K; Barkovich KJ; Kumarasamy V; Wijeratne TU; Bunch KL; Tripathi S; Knudsen ES; Witkiewicz AK; Shokat KM; Rubin SM
Science; 2019 Dec; 366(6471):. PubMed ID: 31831640
[TBL] [Abstract][Full Text] [Related]
26. The RNA-binding protein LRPPRC promotes resistance to CDK4/6 inhibition in lung cancer.
Zhou W; Wang W; Liang Y; Jiang R; Qiu F; Shao X; Liu Y; Fang L; Ni M; Yu C; Zhao Y; Huang W; Li J; Donovan MJ; Wang L; Ni J; Wang D; Fu T; Feng J; Wang X; Tan W; Fang X
Nat Commun; 2023 Jul; 14(1):4212. PubMed ID: 37452037
[TBL] [Abstract][Full Text] [Related]
27. Genetic evidence for functional dependency of p18Ink4c on Cdk4.
Pei XH; Bai F; Tsutsui T; Kiyokawa H; Xiong Y
Mol Cell Biol; 2004 Aug; 24(15):6653-64. PubMed ID: 15254233
[TBL] [Abstract][Full Text] [Related]
28. An Update on the Clinical Use of CDK4/6 Inhibitors in Breast Cancer.
Robert M; Frenel JS; Bourbouloux E; Rigaud DB; Patsouris A; Augereau P; Gourmelon C; Campone M
Drugs; 2018 Sep; 78(13):1353-1362. PubMed ID: 30143968
[TBL] [Abstract][Full Text] [Related]
29. Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib.
Kwapisz D
Breast Cancer Res Treat; 2017 Nov; 166(1):41-54. PubMed ID: 28741274
[TBL] [Abstract][Full Text] [Related]
30.
Teh JLF; Cheng PF; Purwin TJ; Nikbakht N; Patel P; Chervoneva I; Ertel A; Fortina PM; Kleiber I; HooKim K; Davies MA; Kwong LN; Levesque MP; Dummer R; Aplin AE
Cancer Discov; 2018 May; 8(5):568-581. PubMed ID: 29496664
[TBL] [Abstract][Full Text] [Related]
31. Regulation of PRMT5-MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma.
AbuHammad S; Cullinane C; Martin C; Bacolas Z; Ward T; Chen H; Slater A; Ardley K; Kirby L; Chan KT; Brajanovski N; Smith LK; Rao AD; Lelliott EJ; Kleinschmidt M; Vergara IA; Papenfuss AT; Lau P; Ghosh P; Haupt S; Haupt Y; Sanij E; Poortinga G; Pearson RB; Falk H; Curtis DJ; Stupple P; Devlin M; Street I; Davies MA; McArthur GA; Sheppard KE
Proc Natl Acad Sci U S A; 2019 Sep; 116(36):17990-18000. PubMed ID: 31439820
[TBL] [Abstract][Full Text] [Related]
32. Combination of ZEN-3694 with CDK4/6 inhibitors reverses acquired resistance to CDK4/6 inhibitors in ER-positive breast cancer.
Kharenko OA; Patel RG; Calosing C; van der Horst EH
Cancer Gene Ther; 2022 Jun; 29(6):859-869. PubMed ID: 34385584
[TBL] [Abstract][Full Text] [Related]
33. PROTAC-mediated CDK degradation differentially impacts cancer cell cycles due to heterogeneity in kinase dependencies.
Kumarasamy V; Gao Z; Zhao B; Jiang B; Rubin SM; Burgess K; Witkiewicz AK; Knudsen ES
Br J Cancer; 2023 Oct; 129(8):1238-1250. PubMed ID: 37626264
[TBL] [Abstract][Full Text] [Related]
34. Cyclin-dependent kinase 4/6 inhibitors in hormone receptor-positive early breast cancer: preliminary results and ongoing studies.
Kwapisz D
Breast Cancer; 2018 Sep; 25(5):506-516. PubMed ID: 29700711
[TBL] [Abstract][Full Text] [Related]
35. Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations.
Spring LM; Zangardi ML; Moy B; Bardia A
Oncologist; 2017 Sep; 22(9):1039-1048. PubMed ID: 28706010
[TBL] [Abstract][Full Text] [Related]
36. Cyclin D-CDK subunit arrangement is dependent on the availability of competing INK4 and p21 class inhibitors.
Parry D; Mahony D; Wills K; Lees E
Mol Cell Biol; 1999 Mar; 19(3):1775-83. PubMed ID: 10022865
[TBL] [Abstract][Full Text] [Related]
37. Targeting CDK4/6 in patients with cancer.
Hamilton E; Infante JR
Cancer Treat Rev; 2016 Apr; 45():129-38. PubMed ID: 27017286
[TBL] [Abstract][Full Text] [Related]
38. The safety and efficacy of palbociclib in the treatment of metastatic breast cancer.
Ettl J; Harbeck N
Expert Rev Anticancer Ther; 2017 Aug; 17(8):661-668. PubMed ID: 28649895
[TBL] [Abstract][Full Text] [Related]
39. LncRNA TROJAN promotes proliferation and resistance to CDK4/6 inhibitor via CDK2 transcriptional activation in ER+ breast cancer.
Jin X; Ge LP; Li DQ; Shao ZM; Di GH; Xu XE; Jiang YZ
Mol Cancer; 2020 May; 19(1):87. PubMed ID: 32393270
[TBL] [Abstract][Full Text] [Related]
40. Direct CDKN2 Modulation of CDK4 Alters Target Engagement of CDK4 Inhibitor Drugs.
Green JL; Okerberg ES; Sejd J; Palafox M; Monserrat L; Alemayehu S; Wu J; Sykes M; Aban A; Serra V; Nomanbhoy T
Mol Cancer Ther; 2019 Apr; 18(4):771-779. PubMed ID: 30837298
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
